NRX Pharmaceuticals, Inc NT 10-Q, filed May 14, 2021
NRX Pharmaceuticals, Inc. (NRXP)
NT 10-Q
2021-05-14
For: 2021-03-31
View Original
Added on
October 18, 2026
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
|
OMB
APPROVAL
|
|
OMB
Number: 3235-0058
Expires: February
28, 2022
Estimated
average burden
Hours
per form 2.50
|
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
|
SEC
FILE NUMBER
001-38302
|
|
CUSIP
NUMBER
089482
103
|
(Check One):
☐
Form 10-K ☐ Form 20-F
☐ Form 11-K
☒ Form 10-Q
☐ Form 10-D
☐ Form N-CEN
☐ Form
N-CSR
For
Period Ended: March 31,
2021
☐
Transition Report on Form 10-K
☐
Transition Report on Form 20-F
☐
Transition Report on Form 11-K
☐
Transition Report on Form 10-Q
☐
Transition Report on Form N-SAR
For the Transition Period
Ended: __________________
|
Read Instructions (on back page) Before Preparing Form. Please
Print or Type.
Nothing in this form shall be construed to imply that the
Commission has verified any information contained
herein.
|
If the
notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
N/A
PART I – REGISTRANT INFORMATION
Big Rock Partners Acquisition Corp.
Full
Name of Registrant
N/A
Former
Name if Applicable
2645 N. Federal Highway, Suite
230
Address of Principal Executive Office (Street and
Number)
Delray Beach, FL
33483
City,
State and Zip Code
PART II – RULES 12b-25 (b) AND (c)
If the
subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if
appropriate)
|
☒
|
(a) The
reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or
expense;
(b) The
subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar
day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q or subject distribution
report on Form 10-D, or portion thereof, will be filed on or before
the fifth calendar day following the prescribed due date;
and
(c) The
accountant’s statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
|
PART III – NARRATIVE
State
below in reasonable detail the reasons why the Forms 10-K, 20-F,
11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion
thereof, could not be filed within the prescribed time period.
(Attach extra sheets if needed)
Big Rock Partners Acquisition
Corp. (the “Company”) has determined that it is unable,
without unreasonable effort or expense, to file its Quarterly
Report on Form 10-Q for the quarter ended March 31, 2021
(“Form 10-Q”) by the prescribed due date. The Company
requires additional time to compile and verify the data required to
be included in the Form 10-Q. The Company expects to file the Form
10-Q within the additional time allowed.
PART IV – OTHER INFORMATION
|
(1)
|
Name
and telephone number of person to contact in regard to this
notification
|
||
|
|
Richard
Ackerman
(Name)
|
(310)
(Area
Code)
|
734-2300
(Telephone
Number)
|
|
|
|
||
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such
shorter period that the registrant was required to file such
report(s) been filed? If answer is no, identify
report(s).
|
Yes
☒ No
☐
|
|
|
|
|
||
|
(3)
|
Is it
anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject
report or portion thereof?
|
Yes
☐
No ☒
|
|
|
|
|
||
|
|
If so,
attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
|
||
BIG ROCK PARTNERS ACQUISITION CORP.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
Date: May 14,
2021
|
By:
|
/s/ Richard
Ackerman
|
|
|
|
|
Richard
Ackerman
|
|
|
|
|
Chairman, President and Chief Executive Officer |
|
INSTRUCTION:
The form may be signed by an executive officer of the registrant or
by any other duly authorized representative. The name and title of
the person signing the form shall be typed or printed beneath the
signature. If the statement is signed on behalf of the registrant
by an authorized representative (other than an executive officer),
evidence of the representative’s authority to sign on behalf
of the registrant shall be filed with the form.
|
ATTENTION
Intentional misstatements or omissions of fact constitute Federal
Criminal Violations (See 18 U.S.C. 1001).
|